Cellectar Biosciences INC NEWCLRB
Recorded
Cellectar Biosciences INC NEW Investor update
Review the key takeaways and the transcript of this earnings call.
Period 0Duration51 min
Key takeaways
- Cellectar Biosciences presented an educational webinar focused on their phospholipid ether (PL) platform for targeted cancer therapy.
- The company's lead clinical program, I-131, is showing promising results in Waldenström's Macroglobulinemia, a rare B-cell malignancy, with an 84% overall response rate and median duration of around 18 months in heavily pretreated patients.
- The platform targets lipid rafts on cancer cells, which are more abundant and stable in tumors, enabling selective delivery of therapeutic payloads.
- Cellectar has demonstrated the platform's ability to deliver various payloads including beta, alpha, and auger emitters, as well as small molecules, siRNA, mRNA, peptides, and molecular glues.
- Preclinical data show effective tumor targeting and retention, including crossing the blood-brain barrier in brain tumor patients and animal models.
- The company is conducting a Phase 1b dose-finding study of their CLR 125 alpha emitter program in four US centers with data expected later this year or early next year.
- Preclinical models show activity of various isotopes in triple negative breast cancer, pancreatic cancer, and other tumor types.
- Cellectar emphasizes the platform's receptor-independent targeting, broad tumor applicability, and ability to overcome tumor microenvironment barriers.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring